Vir Biotech and GSK join the race find COVID-19 antibody treatment
Category: #health  By Pankaj Singh  Date: 2020-09-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Vir Biotech and GSK join the race find COVID-19 antibody treatment

As the entire world awaits a COVID-19 vaccine, the next big thing in battling the disease could come from a class of biotech therapies such as antibodies designed precisely to attack this virus. As per the latest news, GlaxoSmithKline Plc. and Vir Biotechnology, Inc., have reportedly commenced testing of their new experimental antibody on initial-stage Covid-19 patients, entering the global race to find a winner in the class of antiviral drugs to battle the pandemic.

Sources cite that both companies will be testing the long-acting single injection on recently diagnosed high-risk COVID-19 patients for its ability to avoid hospitalization, particularly a life-threatening disease stage.

While speaking about the company’s late entry in clinical trials, George Scangos, CEO at Vir Biotech said that the company spent a significant amount of time in selecting the best-in-class antibody.

According to sources, the antibody is developed not just to block the SARC-COV-2 virus from attacking cells but to recruit immune cells to destroy already infected cells, which otherwise would replicate the virus. The antibody also has been modified to stay effective for numerous months on a single shot and to cling to a part of the SARC-C0V-2’s outer spike protein which has demonstrated no tendency to mutate.

After testing the potential drug on 20 US participants over fourteen days for safety, the trial will expand to 1,300 patients across the globe. In future studies, both companies are planning to run more clinical trials to assess antibody’s ability to stop the infection and treat COVID-19 individuals that are in hospital care.  

Later this year, both companies are also planning to start a clinical trial of a second antibody from the partnership. GSK said that primary outcomes could be available by the end of 2020 and complete outcomes during Q1 2021.

Source credit - https://www.expresspharma.in/covid19-updates/gsk-vir-biotech-to-test-covid-19-antibody-treatment/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Dada Group partners with Ferrero for new snack food retail model
Dada Group partners with Ferrero for new snack food retail model
By Pankaj Singh

The new retail model will help Ferrero improve brand reach to younger online customers in China

Chinese on-demand delivery and retail platform, Dada Group has inked...

Aphena Pharma to complete expansion of Solid Dose Division by April
Aphena Pharma to complete expansion of Solid Dose Division by April
By Pankaj Singh

Aphena Pharma Solutions, a pharmaceutical services provider, has reportedly announced the continuous expansion of its Tennessee-based Solid Dose Division worth $21 million. This division is expected to be completed by ...

Canada-based CloudMD buys CMD to expand medical database
Canada-based CloudMD buys CMD to expand medical database
By Pankaj Singh

CloudMD Software & Services Inc., a virtual medical care solutions provider based in Canada, has reportedly announced that it has completed the acquisition of the Canadian Medical Directory (CMD)- the nation’...